Elyiahu Rubin
Endocrinology, Diabetes & Metabolism · Las Vegas, NVNPI 1619967502
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NV, where the typical reported total is $4,060.
Across 46 payments — averaging $97.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$478
- Abbott$470
- Corcept Therapeutics$265
- Esperion Therapeutics, Inc.$233
- Otsuka America Pharmaceutical, Inc.$227
- Recordati_rare_diseases_inc.$218
- plus $3K from 20 others
What the payments were for
- Food & beverage$4,472100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 4 | $478 |
| Abbott | 6 | $470 |
| Corcept Therapeutics | 2 | $265 |
| Esperion Therapeutics, Inc. | 2 | $233 |
| Otsuka America Pharmaceutical, Inc. | 2 | $227 |
| Recordati_rare_diseases_inc. | 2 | $218 |
| Sanofi-aventis U.S. LLC | 2 | $211 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $194 |
| E.r. Squibb & Sons, L.L.C. | 2 | $192 |
| Ascensia Diabetes Care US Inc. | 1 | $166 |
| Medtronic | 2 | $161 |
| Neurocrine Biosciences, Inc. | 1 | $138 |
| Boehringer Ingelheim | 2 | $129 |
| Kyowa Kirin, Inc. | 1 | $128 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| Lilly USA, LLC | 1 | $120 |
| Averitas Pharma Inc. | 1 | $119 |
| Amgen | 1 | $118 |
| AbbVie | 1 | $117 |
| Ipsen Biopharmaceuticals, Inc | 1 | $117 |
| Novo Nordisk | 1 | $113 |
| Ultragenyx Pharmaceutical Inc. | 1 | $111 |
| Merck | 1 | $109 |
| AstraZeneca | 1 | $96 |
| Biomarin Pharmaceutical Inc. | 1 | $95 |
| Bridgebio Pharma, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYCAPSSA$272
- Korlym$265
- NEXLETOL$233
- JYNARQUE$227
- MYALEPT$206
- CARDIOMEMS$142
- MINIMED 780G$140
- CRENESSITY$138
- ISTURISA$130
- NEXLIZET$124
- ONPATTRO$122
- MOUNJARO$120
- Qutenza$119
- EVENITY$118
- SOMATULINE DEPOT$117
- TZIELD$115
- FREESTYLE LIBRE 3$114
- Ozempic$113
- CRYSVITA$111
- STEGLATRO$109
How this compares
$4,472 in reported general payments places this provider in the 50th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Other endocrinology, diabetes & metabolism in Las Vegas
- Samer NakhleLas Vegas$466K
- Chakravarthy KannanLas Vegas$144K
- Michael UzmannLas Vegas$77K
- Molouk RahnemaLas Vegas$73K
- Nicholas VernettiLas Vegas$62K
- Firhaad IsmailLas Vegas$47K
- Bijan AhrariLas Vegas$47K
- Freddie ToffelLas Vegas$33K
- Serena KlughLas Vegas$14K
- Betsy PalalLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.